El Shafie, Rami

[["dc.bibliographiccitation.firstpage","1916"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Küchler, Maike; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","El Shafie, Rami A.; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Adeberg, Sebastian; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Herfarth, Klaus; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","König, Laila; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Lang, Kristin; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Hörner-Rieber, Juliane; 4Heidelberg Institute of Radiation Oncology (HIRO), INF 400, 69120 Heidelberg, Germany; juliane.hoerner-rieber@med.uni-heidelberg.de"],["dc.contributor.affiliation","Plinkert, Peter Karl; 9Department of Otolaryngology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; peter.plinkert@med.uni-heidelberg.de"],["dc.contributor.affiliation","Wick, Wolfgang; 8Department of Neurology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; wolfgang.wick@med.uni-heidelberg.de"],["dc.contributor.affiliation","Sahm, Felix; 3Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Heidelberg, INF 280, 69120 Heidelberg, Germany; felix.sahm@med.uni-heidelberg.de"],["dc.contributor.affiliation","Sprengel, Simon David; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Debus, Jürgen; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Bernhardt, Denise; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.author","Küchler, Maike"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Herfarth, Klaus"],["dc.contributor.author","König, Laila"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Hörner-Rieber, Juliane"],["dc.contributor.author","Plinkert, Peter Karl"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Sahm, Felix"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Sprengel, Simon David"],["dc.contributor.author","Debus, Jürgen"],["dc.date.accessioned","2022-05-02T08:09:33Z"],["dc.date.available","2022-05-02T08:09:33Z"],["dc.date.issued","2022"],["dc.date.updated","2022-05-05T11:24:31Z"],["dc.description.abstract","Background: To evaluate differences in local tumor control (LC), symptoms and quality of life (QOL) of 261 patients with VS after stereotactic radiosurgery/hypofractionated stereotactic radiotherapy (SRS/HFSRT) vs. fractionated radiotherapy (FRT) vs. fractionated proton therapy (FPT) were studied. Methods: For SRS/HFSRT (n = 149), the median fraction dose applied was 12 Gy. For FRT (n = 87) and FPT (n = 25), the median cumulative doses applied were 57.6 Gy and 54 Gy (RBE), respectively. FRT and FPT used single median doses of 1.8 Gy/Gy (RBE). Median follow-up was 38 months. We investigated dosimetry for organs at risk and analyzed toxicity and QOL by sending out a questionnaire. Results: LC was 99.5% at 12 months after RT with no statistical difference between treatment groups (p = 0.19). LC was significantly lower in NF2 patients (p = 0.004) and in patients with higher tumor extension grade (p = 0.039). The hearing preservation rate was 97% at 12 months after RT with no statistical difference between treatment groups (p = 0.31). Facial and trigeminal nerve affection after RT occurred as mild symptoms with highest toxicity rate in FPT patients. Conclusion: SRS/HFSRT, FRT and FPT for VS show similar overall clinical and functional outcomes. Cranial nerve impairment rates vary, potentially due to selection bias with larger VS in the FRT and FPT group."],["dc.description.abstract","Background: To evaluate differences in local tumor control (LC), symptoms and quality of life (QOL) of 261 patients with VS after stereotactic radiosurgery/hypofractionated stereotactic radiotherapy (SRS/HFSRT) vs. fractionated radiotherapy (FRT) vs. fractionated proton therapy (FPT) were studied. Methods: For SRS/HFSRT (n = 149), the median fraction dose applied was 12 Gy. For FRT (n = 87) and FPT (n = 25), the median cumulative doses applied were 57.6 Gy and 54 Gy (RBE), respectively. FRT and FPT used single median doses of 1.8 Gy/Gy (RBE). Median follow-up was 38 months. We investigated dosimetry for organs at risk and analyzed toxicity and QOL by sending out a questionnaire. Results: LC was 99.5% at 12 months after RT with no statistical difference between treatment groups (p = 0.19). LC was significantly lower in NF2 patients (p = 0.004) and in patients with higher tumor extension grade (p = 0.039). The hearing preservation rate was 97% at 12 months after RT with no statistical difference between treatment groups (p = 0.31). Facial and trigeminal nerve affection after RT occurred as mild symptoms with highest toxicity rate in FPT patients. Conclusion: SRS/HFSRT, FRT and FPT for VS show similar overall clinical and functional outcomes. Cranial nerve impairment rates vary, potentially due to selection bias with larger VS in the FRT and FPT group."],["dc.identifier.doi","10.3390/cancers14081916"],["dc.identifier.pii","cancers14081916"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/107409"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-561"],["dc.relation.eissn","2072-6694"],["dc.title","Outcome after Radiotherapy for Vestibular Schwannomas (VS)—Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]